DK175406B1 - Antistof-enzymkonjugater i kombination med prolægemidler til afgivelse af cytotoxiske midler til tumorceller - Google Patents

Antistof-enzymkonjugater i kombination med prolægemidler til afgivelse af cytotoxiske midler til tumorceller Download PDF

Info

Publication number
DK175406B1
DK175406B1 DK198804341A DK434188A DK175406B1 DK 175406 B1 DK175406 B1 DK 175406B1 DK 198804341 A DK198804341 A DK 198804341A DK 434188 A DK434188 A DK 434188A DK 175406 B1 DK175406 B1 DK 175406B1
Authority
DK
Denmark
Prior art keywords
antibody
prodrug
enzyme
conjugate
tumor
Prior art date
Application number
DK198804341A
Other languages
Danish (da)
English (en)
Other versions
DK434188D0 (da
DK434188A (da
Inventor
Mark G Saulnier
Joseph P Brown
Peter D Senter
David E Kerr
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/211,301 external-priority patent/US4975278A/en
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of DK434188D0 publication Critical patent/DK434188D0/da
Publication of DK434188A publication Critical patent/DK434188A/da
Application granted granted Critical
Publication of DK175406B1 publication Critical patent/DK175406B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
DK198804341A 1987-08-04 1988-08-03 Antistof-enzymkonjugater i kombination med prolægemidler til afgivelse af cytotoxiske midler til tumorceller DK175406B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8138287A 1987-08-04 1987-08-04
US8138287 1987-08-04
US16106888A 1988-02-26 1988-02-26
US16106888 1988-02-26
US21130188 1988-06-29
US07/211,301 US4975278A (en) 1988-02-26 1988-06-29 Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells

Publications (3)

Publication Number Publication Date
DK434188D0 DK434188D0 (da) 1988-08-03
DK434188A DK434188A (da) 1989-02-05
DK175406B1 true DK175406B1 (da) 2004-09-27

Family

ID=27373967

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198804341A DK175406B1 (da) 1987-08-04 1988-08-03 Antistof-enzymkonjugater i kombination med prolægemidler til afgivelse af cytotoxiske midler til tumorceller

Country Status (19)

Country Link
EP (2) EP0540859B1 (ko)
JP (2) JP2738414B2 (ko)
KR (1) KR930006757B1 (ko)
AT (2) ATE118354T1 (ko)
AU (1) AU614532B2 (ko)
CA (1) CA1336887C (ko)
DE (2) DE3853028T2 (ko)
DK (1) DK175406B1 (ko)
EG (1) EG18751A (ko)
ES (1) ES2068191T3 (ko)
FI (1) FI98197C (ko)
GR (1) GR3015065T3 (ko)
HU (1) HU207230B (ko)
IE (2) IE68309B1 (ko)
IL (1) IL87319A (ko)
NO (1) NO178138C (ko)
NZ (1) NZ225599A (ko)
PT (2) PT88187B (ko)
YU (1) YU150888A (ko)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
WO1990007929A1 (en) * 1989-01-23 1990-07-26 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
GB8907617D0 (en) * 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
DE3935016A1 (de) * 1989-10-20 1991-04-25 Behringwerke Ag Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten
US5270196A (en) * 1989-10-20 1993-12-14 Bristol-Myers Squibb Company Arylsulfatase from streptomyces
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
FI94362C (fi) * 1989-10-20 1995-08-25 Squibb Bristol Myers Co Oleellisesti puhdistettu sulfataasi, menetelmä sen valmistamiseksi ja sitä tuottava Streptomyces-kanta
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
EP0505357B1 (en) * 1989-12-11 1999-03-10 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
WO1991009134A1 (en) * 1989-12-15 1991-06-27 Takeda Chemical Industries, Ltd. Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics
GB9001641D0 (en) * 1990-01-24 1990-03-21 Imp Cancer Res Tech Compounds
KR920007937B1 (ko) * 1990-01-30 1992-09-19 현대자동차 주식회사 밸브시트용 철(Fe)계 소결합금
DE4002888A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten
EP0527189A1 (en) * 1990-04-25 1993-02-17 PHARMACIA & UPJOHN COMPANY Novel cc-1065 analogs
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
GB9200417D0 (en) 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
DE4233152A1 (de) 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5459248A (en) * 1993-11-04 1995-10-17 Bristol-Myers Squibb Company Process of preparing etoposide phosphate and etoposide
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
US5516679A (en) * 1994-12-23 1996-05-14 Bristol-Myers Squibb Company Penicillin V amidohydrolase gene from Fusarium oxysporum
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
JPH1160499A (ja) * 1997-08-22 1999-03-02 Hiroshi Maeda 抗腫瘍剤
US6159706A (en) * 1997-12-23 2000-12-12 Newbiotics, Inc. Application of enzyme prodrugs as anti-infective agents
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
PL200134B1 (pl) 1999-05-07 2008-12-31 Genentech Inc Zastosowanie przeciwciała anty-CD20
US7514067B2 (en) 2000-04-25 2009-04-07 President And Fellows Of Harvard College Methods for tumor diagnosis and therapy
WO2001093826A1 (fr) * 2000-06-06 2001-12-13 Sumitomo Pharmaceuticals Company, Limited Preparations polymere synthetiques biocompatibles
US7445802B2 (en) 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
AU2002358086B2 (en) * 2001-12-03 2009-06-04 Universitatsklinikum Charite Der Humboldt-Universitat Zu Berlin Technologie Transferstelle Podophyllotoxins as antiproliferative agents
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
DE602005023138D1 (de) * 2004-04-15 2010-10-07 Genencor Int Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept
EP2061493A4 (en) * 2006-08-21 2011-01-12 Essential Skincare Llc COMPOSITIONS FOR REDUCING OR PREVENTING SKIN CANCER
BR112020013244A2 (pt) * 2018-01-04 2020-12-01 Shanghai Lumosa Therapeutics Co., Ltd. proteínas de fusão de anticorpo citosina-desaminase de domínio único

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1578734A (ko) * 1967-11-28 1969-08-22
FR2122695A5 (en) * 1971-01-20 1972-09-01 Rhone Poulenc Sa Antibiotics duborimycin and 27706rp - by reduction of daunorubicin and adriamycin
FR2397425A1 (fr) 1977-07-11 1979-02-09 Rhone Poulenc Ind Nouveaux derives de la daunorubicine, leur preparation et les compositions qui les contiennent
CA1168150A (en) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
FR2523445A1 (fr) 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
EP0142905A2 (en) * 1983-03-30 1985-05-29 Bio-Response Inc. Therapeutic substance for treating diseases such as cancer
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
EP0202245A1 (en) * 1984-11-23 1986-11-26 Sri International C-glycosidic adriamycin analogs
US4906562A (en) 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
DE3500023A1 (de) * 1985-01-02 1986-07-10 Farmitalia Carlo Erba S.p.A., Mailand/Milano 4'-desoxyanthracyclinester
FR2584294B1 (fr) 1985-07-08 1992-02-21 Berdal Pascal Compositions pharmaceutiques a visee cytotrophique
GB8528761D0 (en) * 1985-11-22 1985-12-24 Axon Healthcare Ltd Enzyme-coupled antibodies
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems

Also Published As

Publication number Publication date
DE3856112D1 (de) 1998-02-19
NO178138B (no) 1995-10-23
KR890003408A (ko) 1989-04-14
IL87319A0 (en) 1990-02-09
NO883414L (no) 1989-02-06
IE68309B1 (en) 1996-06-12
AU614532B2 (en) 1991-09-05
EG18751A (en) 1993-12-30
JPH02223532A (ja) 1990-09-05
KR930006757B1 (ko) 1993-07-23
FI98197C (fi) 1997-05-12
PT101702B (pt) 1999-11-30
DE3853028T2 (de) 1995-12-14
ATE118354T1 (de) 1995-03-15
DE3856112T2 (de) 1998-08-27
HU207230B (en) 1993-03-29
HUT47437A (en) 1989-03-28
ATE162196T1 (de) 1998-01-15
NO178138C (no) 1996-01-31
DE3853028D1 (de) 1995-03-23
YU150888A (en) 1990-06-30
JP2738414B2 (ja) 1998-04-08
DK434188D0 (da) 1988-08-03
IE882379L (en) 1989-02-04
EP0302473A2 (en) 1989-02-08
PT88187A (pt) 1989-06-30
FI883597A0 (fi) 1988-08-01
FI98197B (fi) 1997-01-31
IL87319A (en) 1995-08-31
EP0302473A3 (en) 1990-01-17
JPH10130295A (ja) 1998-05-19
DK434188A (da) 1989-02-05
GR3015065T3 (en) 1995-05-31
EP0540859B1 (en) 1998-01-14
JP3127136B2 (ja) 2001-01-22
EP0540859A1 (en) 1993-05-12
AU2020188A (en) 1989-05-25
CA1336887C (en) 1995-09-05
EP0302473B1 (en) 1995-02-15
NZ225599A (en) 1991-09-25
NO883414D0 (no) 1988-08-02
PT101702A (pt) 1996-01-31
ES2068191T3 (es) 1995-04-16
PT88187B (pt) 1995-12-29
FI883597A (fi) 1989-02-05
IE950981L (en) 1989-02-04

Similar Documents

Publication Publication Date Title
DK175406B1 (da) Antistof-enzymkonjugater i kombination med prolægemidler til afgivelse af cytotoxiske midler til tumorceller
US4975278A (en) Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DK175174B1 (da) Anthracyclinimmunokonjugater med en hidtil ukendt linker og fremgangsmåder til fremstilling deraf
Senter et al. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates
US7049316B2 (en) Prodrugs of CC-1065 analogs
EP1391213A1 (en) Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
CZ20033477A3 (en) Conjugates of an antibody to CD44 and a maytansinoid
NO315162B1 (no) Forbindelser for anvendelse som lysosomale, enzymspaltbare antitumorlegemiddelkonjugater og fremgangsmåte for fremstilling derav
US5010176A (en) Antibody-drug conjugates
AU2017389094A1 (en) Aptamer-drug conjugate and use thereof
CA2055062A1 (en) Prodrugs for beta-lactamase and uses thereof
CN115666642A (zh) 含有α-烯醇酶抗体的药物缀合物和其用途
EP1417974A1 (en) Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
DD281962A5 (de) Verfahren zur herstellung einer kombination aus einem antikoerper-enzymkonjugat und einer prodrug
NO178341B (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive anthracyclinderivater
Conjugates in Vitro Enhancement of the
AU2002313471A1 (en) Cytotoxic CD44 antibody immunoconjugates

Legal Events

Date Code Title Description
PUP Patent expired